Abstract View

Author(s): Abishek S1*1, S.Lavanya22, Balakrishnan R33

Email(s): 1abisheksaravanan3@gmail.com

Address:

    1. M.Pharm, Department of Pharmacy Practice, PSG College of Pharmacy,Coimbatore 2. Professor, Department of Pharmacy Practice, PSG College of Pharmacy, Coimbatore 3. Head and Department of Neurology, PSG Hospital, Coimbatore

Published In:   Volume - 4,      Issue - 6,     Year - 2025

DOI: https://doi.org/10.71431/IJRPAS.2025.4608  

 View HTML        View PDF

Please allow Pop-Up for this website to view PDF file.

ABSTRACT:
There are few treatment options for ischemic stroke, which mostly focuses on reperfusion, and it continues to be a leading cause of mortality and permanent disability globally. Neuroprotective medicines are desperately needed in order to improve functional recovery and encourage brain restoration. The capacity of sovateltide, a novel selective endothelin B (ETB) receptor agonist, to promote neurogenesis, angiogenesis, and decrease neuronal death has made it a viable candidate. This review synthesizes current preclinical and clinical evidence regarding the efficacy and safety of sovateltide in ischemic stroke management. Preclinical studies in rodent models demonstrated significant reductions in infarct size, improved motor function, increased expression of neurotrophic factors, and enhanced neural stem cell proliferation. According to clinical data from Phase II and III randomized controlled trials, patients receiving sovateltide had noticeably better functional outcomes than those receiving standard care alone, as indicated by the modified Rankin Scale (mRS), National Institutes of Health Stroke Scale (NIHSS), and Barthel Index. Importantly, no major adverse effects were reported, supporting its favorable safety profile. These findings indicate that sovateltide offers neuroprotective benefits beyond current reperfusion therapies. Future large-scale trials and long-term follow-up studies are warranted to confirm its therapeutic potential and optimize its clinical use in ischemic stroke treatment.

Cite this article:
Abishek S, S.Lavanya, Balakrishnan R. Neuroprotective Role of Sovateltide in Ischemic Stroke: A Review of Preclinical and Clinical Evidence. IJRPAS, June 2025; 4 (6): 80-85.DOI: https://doi.org/https://doi.org/10.71431/IJRPAS.2025.4608


1.      Mergenthaler P, Dirnagl U, Kunz A. Ischemic stroke: basic pathophysiology and clinical implication. InNeuroscience in the 21st century: From basic to clinical 2022 Oct 18 (pp. 3807-3827). Cham: Springer International Publishing.

2.      Tsivgoulis G, Katsanos AH, Sandset EC, Turc G, Nguyen TN, Bivard A, Fischer U, Khatri P. Thrombolysis for acute ischaemic stroke: current status and future perspectives. The Lancet Neurology. 2023 May 1;22(5):418-29.

3.      Fisher M, Savitz SI. Pharmacological brain cytoprotection in acute ischaemic stroke—renewed hope in the reperfusion era. Nature Reviews Neurology. 2022 Apr;18(4):193-202.

4.      Ranjan AK, Briyal S, Khandekar D, Gulati A. Sovateltide (IRL-1620) affects neuronal progenitors and prevents cerebral tissue damage after ischemic stroke. Canadian Journal of Physiology and Pharmacology. 2020;98(9):659-66.

5.      Ranjan AK, Briyal S, Gulati A. Sovateltide (IRL-1620) activates neuronal differentiation and prevents mitochondrial dysfunction in adult mammalian brains following stroke. Scientific reports. 2020 Jul 29;10(1):12737.

6.      Mavridis T, Mavridi A, Karampela E, Galanos A, Gkiokas G, Iacovidou N, Xanthos T. Sovateltide (ILR-1620) Improves Motor Function and Reduces Hyperalgesia in a Rat Model of Spinal Cord Injury. Neurocritical Care. 2024 Oct;41(2):455-68.

7.      Ramos MD, Briyal S, Prazad P, Gulati A. Neuroprotective effect of sovateltide (IRL 1620, PMZ 1620) in a neonatal rat model of hypoxic-ischemic encephalopathy. Neuroscience. 2022 Jan 1;480:194-202.

8.      Gulati A, Agrawal N, Vibha D, Misra UK, Paul B, Jain D, Pandian J, Borgohain R. Safety and efficacy of sovateltide (IRL-1620) in a multicenter randomized controlled clinical trial in patients with acute cerebral ischemic stroke. CNS drugs. 2021 Jan;35:85-104

9.      Gulati A, Adwani SG, Vijaya P, Agrawal NR, Ramakrishnan TC, Rai HP, Jain D, Sundarachary NV, Pandian JD, Sardana V, Sharma M. Efficacy and Safety of Sovateltide in Patients with Acute Cerebral Ischaemic Stroke: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase III Clinical Trial. Drugs. 2024 Dec;84(12):1637-50.

10.  Haupt M, Gerner ST, Bähr M, Doeppner TR. Neuroprotective strategies for ischemic stroke—future perspectives. International journal of molecular sciences. 2023 Feb 22;24(5):4334.

11.  Ranjan AK, Gulati A. Sovateltide mediated endothelin B receptors agonism and curbing neurological disorders. International Journal of Molecular Sciences. 2022 Mar 15;23(6):3146.

12.  Berlet R, Anthony S, Brooks B, Wang ZJ, Sadanandan N, Shear A, Cozene B, Gonzales-Portillo B, Parsons B, Salazar FE, Lezama Toledo AR. Combination of stem cells and rehabilitation therapies for ischemic stroke. Biomolecules. 2021 Sep 6;11(9):1316.

Related Images:



Recent Images



A Review of Current Formulation Trends and Technological Advancements
Natural solution for Alopacia: A review of Herbal Stimulants for Hair Growth and Hair Fall
Edible Insect and Their Future in India
Formulation and Evaluation of Gastroretentive Floating Microspheres of Labetalol Hydrochloride
Analysis of High Incidences and Etiological Factors of Tuberculosis in the Region of Malegaon: An Observational Study
Comprehensive Phytochemical Screening and Quantification of Bioactive Compounds in Ziziphus spina-christi for Herbal Cosmetics
Evaluation of Anti-Ulcer Activity of Chloroform and Alcoholic Extracts of Leaves of Mimusops elengi
Disease Caused by Heavy Metals and Dust: A Review
Respiratory Problems Caused Due to Heavy Metals and Dust
Neurological Complications among Pregnant and Post Partum Mothers in a Private Hospital, Yogyakarta, Indonesia

Tags